|
Emerging Diagnostic Markers in Alzheimer’s DiseasePublished by: Decision Resources Published: Jun. 14, 2005 - 26 Pages The price of this report has been reduced due to its age. The original price was $1,900 for PDF E-mail From Publisher.Table of Contents
AbstractCurrently, Alzheimer’s disease (AD) is diagnosed based on patient clinical history and exclusion of other neurological disorders. Because early signs of AD are hard to distinguish from normal signs of aging, most patients are not diagnosed until neuronal damage is extensive. A diagnostic marker would enable physicians to diagnose more AD patients earlier and begin drug treatment when it could be most effective. The AD therapeutics market would also benefit: early diagnosis and treatment translates to more therapy sales over longer treatment periods. In this report, we review AD diagnostic markers currently in use and in development, the main players in the AD diagnostics arena, and the impact that these markers will have on the U.S. AD market over the next ten years.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||